Targeted Mesoporous Silica Nanocarriers in Oncology

Author(s): Alejandro Baeza, Maria Vallet-Regi*.

Journal Name: Current Drug Targets

Volume 19 , Issue 3 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Background: Cancer is one of the major leading causes of death worldwide and its prevalence will be higher in the coming years due to the progressive aging of the population. The development of nanocarriers in oncology has provided a new hope in the fight against this terrible disease.

Objective: Among the different types of nanoparticles which have been reported in the scientific literature, mesoporous silica nanoparticles (MSNs) are very promising materials due to their inherent properties such as high loading capacity of many different drugs, excellent biocompatibility and easy functionalization.

Results: This review presents the current state of the art related to the development of mesoporous silica nanocarriers for antitumoral therapy paying special attention on targeted MSN able to selectively destroy tumoral cells, reducing the side damage in healthy ones, and the basic principles of targeting tumoral tissues and cells.

Conclusions: MSNs constitute a promising nanomaterial for drug delivery applications in antitumoral therapy as a consequence of its unique properties such as excellent biocompatibility, high loading capacity, robustness, easy production and existence of multiple strategies for their functionalization with a myriad of bio-organic moieties. In the coming years, the clever application of this material would provide novel alternatives for the treatment of this complex disease.

Keywords: Nanomedicine, targeted nanocarriers, nanooncology, mesoporous silica nanoparticles, cancer, nanoparticles.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [213 - 224]
Pages: 12
DOI: 10.2174/1389450117666160603023037
Price: $65

Article Metrics

PDF: 31
PRC: 1